Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).
Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).
Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy and chemotherapy (Abstract 223).
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
